INIS
patients
100%
risks
61%
drugs
44%
populations
36%
fractures
33%
cancer
27%
comparative evaluations
24%
diseases
23%
data
19%
control
19%
doses
17%
hazards
13%
concentration
13%
mortality
11%
hospitals
11%
lung cells
10%
kidneys
10%
validation
10%
netherlands
10%
plasma
9%
arthritis
9%
men
9%
reviews
8%
therapy
8%
interventions
8%
women
7%
humans
7%
levels
7%
design
7%
metastases
7%
insulin
6%
sex
6%
blood
6%
adults
6%
toxicity
6%
inflammation
6%
monitoring
6%
cost
6%
glucocorticoids
6%
diabetes mellitus
6%
incidents
5%
united kingdom
5%
receptors
5%
bone joints
5%
assessments
5%
variations
5%
range
5%
Keyphrases
Clinical Practice Research Datalink
13%
Fracture Risk
12%
Population-based Cohort Study
11%
Netherlands
11%
Osteoporotic Fractures
10%
Dutch
10%
Confidence Interval
9%
Non-small Cell Lung Cancer (NSCLC)
8%
Type 2 Diabetes Mellitus (T2DM)
8%
Incidence Rate
7%
Rheumatoid Arthritis
6%
Hazard Ratio
6%
Hip Fracture
6%
Osimertinib
5%
United Kingdom
5%
Chronic Obstructive Pulmonary Disease
5%
All-cause Mortality
5%
Population-based Case-control Study
5%
Pharmacokinetics
5%
Clinical Practice
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
22%
Pharmacokinetics
13%
Fragility Fracture
10%
Non Small Cell Lung Cancer
10%
Hip Fracture
8%
Case-Control Study
7%
Non Insulin Dependent Diabetes Mellitus
7%
Adverse Drug Reaction
6%
Glucocorticoid
6%
Malignant Neoplasm
5%
Disease
5%